F. Halley

发表

Functionalization of saturated hydrocarbons. 14. Further studies on the mechanism of Gif-type systems

M. Schmitt, D. Barton, G. Balavoine, 1989 .

Concomitant Inhibition of PI 3 K b andBRAForMEK in PTEN-De fi cient / BRAF-Mutant Melanoma Treatment : Preclinical Assessment of SAR 260301 Oral PI 3 K b-Selective Inhibitor H el

C. García-echeverría, C. Lengauer, L. Vincent, 2016 .

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.

P. Chamiot-Clerc, C. Leriche, F. Halley, 2016, Bioorganic & medicinal chemistry letters.

Benzylic oxidation by the gifIV system

D. Barton, N. Ozbalik, F. Halley, 1989 .

New non peptidic C5a receptor antagonists

P. Lockey, I. McLay, A. Morley, 1997 .

Identification of a non peptidic RANTES antagonist.

P. Lockey, I. McLay, R. Williams, 1998, Bioorganic & medicinal chemistry letters.

Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors.

J. Nicolas, C. García-echeverría, C. Lengauer, 2014, Bioorganic & medicinal chemistry letters.

Synthesis of 5-Cyanoindazole and 1-Methyl and 1-Aryl-5-Cyanoindazoles

F. Halley, X. Sava, 1997 .

Synthesis of 1,3-disubstituted-pyrrolo[2,1-a]isoquinoline-2-carboxylic acids, esters and amides

D. Lythgoe, M. Hursthouse, C. Lehmann, 1993 .

Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Journal of medicinal chemistry.

An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.

Stephen D Pickett, Imtiaz Ahmed, Frank Halley, 2002, Journal of medicinal chemistry.

The chemistry of pentavalent organobismuth reagents: Part XI. Reactions with sterically hindered phenols

D. Barton, C. Giannotti, F. Halley, 1988 .

Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Jean-Pierre Marquette, Magali Mathieu, Thomas Bertrand, 2014, Journal of medicinal chemistry.

Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivatives.

P. Lockey, A. Roach, I. McLay, 1998, Journal of medicinal chemistry.

Differential Water Thermodynamics Determine PI3K-Beta/Delta Selectivity for Solvent-Exposed Ligand Modifications

Benoit Robert, Woody Sherman, Daniel Robinson, 2016, J. Chem. Inf. Model..

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, C. García-echeverría, L. Debussche, 2020, Molecular Cancer Therapeutics.

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, L. Debussche, M. Levit, 2020 .

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

I. McLay, S. Phipps, M. Belvisi, 2001, Bioorganic & medicinal chemistry.

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

I. McLay, N. Wilsher, M. Foster, 2001, Bioorganic & medicinal chemistry letters.

On the mechanism of the Gif and Gif-Orsay systems for the selective substitution of saturated hydrocarbons

D. Barton, G. Balavoine, J. Boivin, 1989 .

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

M. Mathieu, C. García-echeverría, M. Levit, 2019, Journal of medicinal chemistry.

Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer

C. García-echeverría, C. Winter, L. Debussche, 2018, Endocrinology.

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.

A. Roach, I. McLay, A. Morley, 2000, Journal of medicinal chemistry.

Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.

M. Dreyer, T. Rooney, D. Lesuisse, 2010, Bioorganic & medicinal chemistry letters.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Bioorganic & medicinal chemistry letters.

Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.

P. Chamiot-Clerc, C. Leriche, F. Halley, 2016, Bioorganic & medicinal chemistry letters.

Abnahme von Blutkulturen

F. Halley, R. Klein, Borde Jp, 2010, Deutsche medizinische Wochenschrift.